While the class of immunotherapies known as checkpoint inhibitors has brought a promising new approach to treating cancer, the development of resistance to these therapies limits the number of patients they benefit. Portage Biotech is building a set of platform technologies and a pipeline of immuno-oncology therapeutic candidates to address this problem. We spoke to Ian Walters, CEO of Portage about the problem of resistance, the company’s pipeline of candidates, and its portfolio-based business model.